1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Appetite (Eating) Disorders – Pipeline Review, H1 2013

Appetite (Eating) Disorders – Pipeline Review, H1 2013

  • March 2013
  • -
  • Global Markets Direct
  • -
  • 80 pages

Appetite (Eating) Disorders – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Appetite (Eating) Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Appetite (Eating) Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Appetite (Eating) Disorders. Appetite (Eating) Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Appetite (Eating) Disorders.
- A review of the Appetite (Eating) Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Appetite (Eating) Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Appetite (Eating) Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Appetite (Eating) Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Appetite (Eating) Disorders - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Appetite (Eating) Disorders Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Appetite (Eating) Disorders 9
Appetite (Eating) Disorders Therapeutics under Development by Companies 11
Appetite (Eating) Disorders Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Appetite (Eating) Disorders Therapeutics - Products under Development by Companies 18
Appetite (Eating) Disorders Therapeutics - Products under Investigation by Universities/Institutes 19
Companies Involved in Appetite (Eating) Disorders Therapeutics Development 20
GlaxoSmithKline plc 20
Shire Plc 21
INSYS Therapeutics, Inc. 22
Helsinn Healthcare S.A. 23
KangLaiTe USA 24
Omeros Corporation 25
Medisyn Technologies, Inc. 26
Kuhnil Pharmaceutical Co., Ltd. 27
Heptares Therapeutics Ltd. 28
Lightlake Therapeutics Inc. 29
Rhythm Pharmaceuticals 30
Appetite (Eating) Disorders - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
GSK-1521498 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
RM-131 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Kanglaite - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
aripiprazole - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
anamorelin hydrochloride - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
anamorelin hydrochloride - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
oxytocin - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
erythromycin propionate - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
Dehydroepiandrosterone + Hormone Replacement Therapy - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
lisdexamfetamine dimesylate - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
GPR101 Antagonist - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
naloxone hydrochloride Intranasal - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
KI-1003 - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Ghrelin Receptor Agonists - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
dronabinol Intavenous - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
Drug targeting Orexin 1 - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
LT-21 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
Dopamine Inhibitor - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
Appetite (Eating) Disorders Therapeutics - Drug Profile Updates 62
Appetite (Eating) Disorders Therapeutics - Discontinued Products 69
Appetite (Eating) Disorders Therapeutics - Dormant Products 70
Appetite (Eating) Disorders - Product Development Milestones 71
Featured News and Press Releases 71
Aug 08, 2012: Lightlake Therapeutics Announces Positive Preliminary Phase II Clinical Trial Results Of Binge Eating Disorder Treatment 71
May 03, 2012: Lightlake Announces Positive Preliminary Phase II Trial Results Of Binge Eating Disorder Treatment Using Naloxone 72
Apr 26, 2012: Shire Reports Positive Top-Line Results From Phase II Study Of Vyvanse In Adults With Binge Eating Disorder 73
Dec 07, 2011: Helsinn Initiates Extension Study In Late-Stage Anamorelin Clinical Program For Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia 75
Dec 07, 2011: Helsinn Initiates Extension Study In Late-Stage Anamorelin Clinical Program For Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia 75
Aug 24, 2011: Helsinn Therapeutics Initiates Phase III Clinical Program To Evaluate Anamorelin In Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia 76
Mar 02, 2011: Omeros Unlocks Orphan GPCRs Linked To Pancreatic Cancer And Cognitive Disorders 76
Nov 03, 2010: Ohr Pharmaceutical Inc. Announces $244,000 Grant Award 77
Apr 26, 2007: Sapphire Therapeutics, Inc. to Present Results From Anamorelin Phase II Cachexia/Anorexia Studies at American Society of Clinical Oncology and Endocrine Society Annual Meetings in June 77
Dec 15, 2005: Sapphire Therapeutics, Inc.'s Oral Ghrelin Mimetic Shows Potential for Treating Cancer Anorexia/Cachexia 78
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 80
Disclaimer 80



List of Tables

Number of Products Under Development for Appetite (Eating) Disorders, H1 2013 9
Products under Development for Appetite (Eating) Disorders - Comparative Analysis, H1 2013 10
Number of Products under Development by Companies, H1 2013 12
Number of Products under Investigation by Universities/Institutes, H1 2013 13
Comparative Analysis by Late Stage Development, H1 2013 14
Comparative Analysis by Mid Clinical Stage Development, H1 2013 15
Comparative Analysis by Early Clinical Stage Development, H1 2013 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 17
Products under Development by Companies, H1 2013 18
Products under Investigation by Universities/Institutes, H1 2013 19
GlaxoSmithKline plc, H1 2013 20
Shire Plc, H1 2013 21
INSYS Therapeutics, Inc., H1 2013 22
Helsinn Healthcare S.A., H1 2013 23
KangLaiTe USA, H1 2013 24
Omeros Corporation, H1 2013 25
Medisyn Technologies, Inc., H1 2013 26
Kuhnil Pharmaceutical Co., Ltd., H1 2013 27
Heptares Therapeutics Ltd., H1 2013 28
Lightlake Therapeutics Inc., H1 2013 29
Rhythm Pharmaceuticals, H1 2013 30
Assessment by Monotherapy Products, H1 2013 31
Assessment by Combination Products, H1 2013 32
Assessment by Stage and Route of Administration, H1 2013 34
Assessment by Stage and Molecule Type, H1 2013 36
Appetite (Eating) Disorders Therapeutics - Drug Profile Updates 62
Appetite (Eating) Disorders Therapeutics - Discontinued Products 69
Appetite (Eating) Disorders Therapeutics - Dormant Products 70



List of Figures

Number of Products under Development for Appetite (Eating) Disorders, H1 2013 9
Products under Development for Appetite (Eating) Disorders - Comparative Analysis, H1 2013 10
Products under Development by Companies, H1 2013 11
Products under Investigation by Universities/Institutes, H1 2013 13
Late Stage Products, H1 2013 14
Mid Clinical Stage Products, H1 2013 15
Early Clinical Stage Products, H1 2013 16
Discovery and Pre-Clinical Stage Products, H1 2013 17
Assessment by Monotherapy Products, H1 2013 31
Assessment by Combination Products, H1 2013 32
Assessment by Route of Administration, H1 2013 33
Assessment by Stage and Route of Administration, H1 2013 34
Assessment by Molecule Type, H1 2013 35
Assessment by Stage and Molecule Type, H1 2013 36

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.